Crinetics Pharmaceuticals Inc.

CRNX

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

Baker Bros. Advisors Driehaus Capital OrbiMed Advisors

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 1,648,869Value: $76.8M

## Signal Note: Baker Bros. Initiates Large Position in CRNX **Note: The reported position value of ~$76.8B appears to be a data error—at recent prices (~$46-50/share), 1,648,869 shares would be worth approximately $76-82M, which is the likely actual position size.** Baker Bros. building a new ~$76-82M position in Crinetics is a high-conviction signal given their concentrated, specialist approach and strong track record in late-stage biotech. CRNX's lead asset **paltusotine**, an oral nonpeptide somatostatin receptor type 2 agonist, has a PDUFA date of **August 8, 2025** for **acromegaly**—positioning this as a pre-catalyst accumulation ahead of a potential first-in-class oral approval that could displace

Driehaus CapitalNEW

More CRNX Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ALKS3 funds ARGX3 funds ARWR3 funds IRON3 funds PRAX3 funds EWTX3 funds SYRE3 funds INSM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Driehaus Capital Initiates $297M Position in CRNX Driehaus's $297M entry into Crinetics likely reflects conviction in macrolithín (CRN04894), a oral selective somatostatin receptor 2 (SST2) agonist in Phase 3 for acromegaly, with topline data expected in 2H 2024. The timing aligns with potential near-term clinical readout that could validate oral SST2 agonists as a competitive alternative to current injectable therapies, de-risking the pipeline ahead of potential regulatory decisions in 2025.